Oral drug for COVID-19 study
18 - 45 years
Trial length :
4 days / 3 nights
1 follow-up visit
We are conducting a study seeking healthy males or females, between the ages of 18 to 45 years
old, with a body weight of between 45kg and 100kg, with a Body Mass Index (BMI) of between 18
and 30 kg/m².
The drug will be delivered orally, in tablet form.
There are 3 phases to the study, of which you can participate in 1 or more, if eligible.
Part 1 (cohorts 1, 3, 4)
An in-house stay of 3 nights / 4 days, with 1 follow-up visit.
Part 2 (cohort 2)
2 in-house stay periods of 3 nights / 4 days, each with 1 follow-up visit.
An in-house stay of 10 nights / 11 days, with 1 follow-up visit.
If you meet the criteria for this study and would like more information, register below or call 1800 727 874.